US Patent

US9415043 — Combination therapy

Composition of Matter · Assigned to Aerie Pharmaceuticals Inc · Expires 2034-03-14 · 8y remaining

Vulnerability score 4/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects compounds and compositions that combine an isoquinoline compound with a prostaglandin or prostaglandin analog for treating glaucoma and/or reducing intraocular pressure.

USPTO Abstract

Described herein are compounds and compositions for treating glaucoma and/or reducing intraocular pressure. Compositions may comprise an isoquinoline compound and a prostaglandin or a prostaglandin analog. Compounds described herein include those in which an isoquinoline compound is covalently linked to a prostaglandin or a prostaglandin analog, and those in which an isoquinoline compound and a prostaglandin free acid together form a salt.

Drugs covered by this patent

Patent Metadata

Patent number
US9415043
Jurisdiction
US
Classification
Composition of Matter
Expires
2034-03-14
Drug substance claim
Yes
Drug product claim
No
Assignee
Aerie Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.